{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023740","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.494213+00:00","generated_at":"2026-05-17T13:13:34.253233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations","bullets":["Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.","Loss from operations improved to $1.3M in Q2 2025 versus $1.4M in the prior year quarter.","Raised $2.4M net in April and June 2025 from sale of senior subordinated notes and warrants to Aditxt (ADTX).","PHEXXI submitted for UAE marketing approval by licensee Pharma 1; SOLOSEC submission expected Q3 2025.","Net loss per share was $(0.02) in Q2 2025 vs net income of $0.02 per share in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023740","json":"https://secwatch.observer/filing/0001641172-25-023740.json","markdown":"https://secwatch.observer/filing/0001641172-25-023740.md","text":"https://secwatch.observer/filing/0001641172-25-023740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/0001641172-25-023740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T13:13:34.253233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}